Involvement of MAPK signaling molecules and Runx2 in the NELL1-induced osteoblastic differentiation  by Bokui, Nobuyuki et al.
FEBS Letters 582 (2008) 365–371Involvement of MAPK signaling molecules and Runx2 in the
NELL1-induced osteoblastic diﬀerentiation
Nobuyuki Bokuia, Takayuki Otanib, Koichi Igarashib, Junichiro Kakuc, Mitsuo Odad,
Tadahiro Nagaokae, Masaharu Senoe, Kenji Tatematsua, Toshihide Okajimaa,
Takashi Matsuzakia, Kang Tingf, Katsuyuki Tanizawaa, Shunichi Kurodaa,*
a Department of Structural Molecular Biology, The Institute of Scientiﬁc and Industrial Research, Osaka University, Osaka 567-0047, Japan
b Katayama Chemical Industries Co., Ltd., Osaka 562-0015, Japan
c Hirai Dental Clinic, Tokyo 132-0035, Japan
d School of Dentistry, Showa University, Tokyo 142-8555, Japan
e Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan
f Section of Orthodontics, UCLA School of Dentistry & Department of Biomedical Enginnering, UCLA School of Engineering,
Los Angeles, CA 90095, USA
Received 26 September 2007; revised 4 December 2007; accepted 4 December 2007
Available online 17 December 2007
Edited by Angel NebredaAbstract NELL1 is an extracellular protein inducing osteo-
genic diﬀerentiation and bone formation of osteoblastic cells.
To elucidate the intracellular signaling cascade evoked by
NELL1, we have shown that NELL1 protein transiently acti-
vates the MAPK signaling cascade, induces the phosphorylation
of Runx2, and promotes the rapid intracellular accumulation of
Tyr-phosphorylated proteins. Unlike BMP2, NELL1 protein
does not activate the Smad signaling cascade. These ﬁndings
suggest that upon binding to a speciﬁc receptor NELL1 transdu-
ces an osteogenic signal through activation of certain Tyr-
kinases associated with the Ras-MAPK cascade, and ﬁnally
leads to the osteogenic diﬀerentiation.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Osteogenic diﬀerentiation of mesenchymal pluripotent cells
is regulated by various soluble proteinous factors [1]. Espe-
cially, BMP (bone morphogenetic protein) was originally iden-
tiﬁed as a molecule that promotes the diﬀerentiation of
mesenchymal cells into an osteoblastic lineage, as suggested
from its abilities not only to induce the expression of osteo-
blastic markers alkaline phosphatase (ALP) and osteocalcin
(OCN) but also to stimulate mineralization [2]. In the BMP
signaling pathways, the Smad proteins play a major role in
osteoblastic diﬀerentiation through activation of the target
genes. Additionally, the runt-related transcription factor 2/
core binding factor a1 (Runx2/Cbfa1) was shown to be indis-
pensable for osteoblast diﬀerentiation and bone formation [3].Abbreviations: hNELL1, human novel EGF-like protein 1; ECM,
extracellular matrix; ALP, alkaline phosphatase; OCN, osteocalcin;
Runx2, runt-related transcription factor 2; aa, amino acid residues;
TSP, thrombospondin; RFC, rat fetal calvarial; OPN, osteopontin
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doi:10.1016/j.febslet.2007.12.006We previously identiﬁed a gene excessively expressed at the
sutures of unilateral coronal synostosis, causing the prema-
ture fusion of the growing cranial bone fronts, and designated
NELL1 [novel epidermal growth factor (EGF)-like protein 1]
[4]. NELL1 protein consists of about 810 amino acid residues
(aa) and harbors an about 20-aa signal peptide, an about 128-
aa laminin G domain [previously known as an N-terminal
thrombospondin (TSP)-like module], ﬁve von Willebrand fac-
tor C domains, and six EGF-like domains including three
Ca2+-binding types [5], as shown in Fig. 1. Concerning phys-
iological functions, the NELL1 gene was shown to induce
osteogenic diﬀerentiation of rat fetal calvarial (RFC) cells,
and the transgenic mice overexpressing the NELL1 gene
exhibited a craniosynostosis (CS)-like phenotype [6]. On the
other hand, the NELL1-deﬁcient mice had reduced levels of
extracellular matrix (ECM) proteins, thereby causing skeletal
defects in the vertebral column and ribcage [7]. These obser-
vations have facilitated recent attempts to examine the thera-
peutic eﬀects of NELL1 protein on bone defects in animal
models [8,9]. However, it has not been elucidated how
NELL1 protein evokes the intracellular signaling cascade in
osteoblasts.
In this study, we have obtained highly puriﬁed recombinant
human novel EGF-like protein 1 (hNELL1) and examined the
direct eﬀects of hNELL1 protein on various osteoblastic cells.
We here show that hNELL1 protein added at a markedly low
molar concentration is able to transiently activate the MAPK
signaling cascade in various osteoblastic cells and transduces
its signals through the Smad-independent signaling cascade.
Furthermore, addition of hNELL1 protein resulted in the
Runx2 phosphorylation and rapid accumulation of Tyr-phos-
phorylated proteins.2. Materials and methods
2.1. Production and puriﬁcation of hNELL1 protein
The hNELL1 cDNA was subcloned into the expression vector pIZT/
V5-His contained in the InsectSelect Glow System (Invitrogen, Carls-
bad, CA), and introduced into the Trichoplusia ni-derived High Five
cells (Invitrogen). The hNELL1 protein secreted in the medium was
collected and puriﬁed as described in Supplementary materials and
methods.blished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic structure of hNELL1 and sequence comparison with laminin G family proteins. Protein motifs were searched in the SMART
database accessible at the SMART website (http://smart.embl-heidelberg.de/) and shown by boxes for the laminin G domain (LG), von Willebrand
factor C domains (V), EGF-like domains (E), and Ca2+-binding EGF-like domains (E*). Signal peptide (aa 1–19) is indicated by a gray bar. Partial
sequence alignment of laminin G domains was carried out by the CLUSTAL W protocol using a BLOSUM62 amino acid substitution matrix
available at the DNA Data Bank of Japan website (http://clustalw.ddbj.nig.ac.jp/). hNELL1, human NELL1; hLAMA3, human laminin a3 chain;
mLAMA3, mouse laminin a3 chain; hCOLA1, human collagen 11 a3 chain; and hTSP1, human thrombospondin-1. Residue numbers of the core
regions of laminin G domains are indicated in the margins. Strand assignments for b-strands (C–J) are according to Hohenester et al. [25]. Conserved
amino acid residues are shaded. Glu residues presumed as the binding site for integrin a6b1 are indicated in boldface.
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RFC cells, s mouse osteoblast cell line MC3T3-E1, a human osteo-
sarcoma cell line Saos-2, a mouse myoblast-like cell line C2C12, and a
mouse mesenchymal stem cell line C3H10T1/2 were obtained and cul-
tured as described in Supplementary materials and methods.
2.3. Small interfering RNA experiments
Ras small interfering RNA (siRNA) assays were performed using a
commercially available Ras siRNA/siAb assay kit from Dharmacom
(Upstate, Lake Placid, NY). After C3H10T1/2 cells were grown to
50% conﬂuence, cells were transfected with SMARTpool Ras and
non-speciﬁc Control Pool (negative control) siRNA oligo mixtures
using Lipofectamine RNAi Max (Invitrogen), according to the manu-
factures protocol. Transfection of Ras siRNA was conﬁrmed by Wes-
tern blotting using an anti-Ras antibody (clone RAS10). Seventy two
hours after transfection, cells were subjected to Western blotting and
ELISA according to the protocols described above.
2.4. Immunoprecipitation assay for Runx2
Runx2 protein in RFC cells were immunoprecipitated with anti-
Runx2 antibody (Cat. R9403, Sigma), and then analyzed with a
horseradish peroxidase-conjugated anti-phospho-Ser antibody (Cat.
ab9334, abcam, Cambridge, UK), as described in Supplementary
materials and methods.
2.5. Pull down assay using hNELL1-VH
Cell lysates of hNELL1-VH-treated RFC cells were immunoprecip-
itated with an anti-V5 tag antibody, and then analyzed with an anti-
phospho-Tyr antibody (clone 4G10, Upstate, Billerica, MA), as de-
scribed in Supplementary materials and methods.3. Results and discussion
3.1. Induction of osteomarkers
RFC cells were treated directly with the puriﬁed hNELL1-
VH protein (see Supplementary Results and SupplementaryFig. 1). As shown in Fig. 2A, in the cells cultured for 3 days
after the treatment, the activity of ALP increased nearly in a
dose dependent manner of hNELL1-VH protein added. Addi-
tion of 50–100 ng/ml hNELL1-VH protein was suﬃcient to in-
crease the ALP activity by about 7-folds. Hence, we have
added 100 ng/ml hNELL1-VH protein constantly in the subse-
quent experiments, unless otherwise described. The ALP
activity induced after the treatment with 50–100 ng/ml
hNELL1-VH protein was only about a half that induced after
the treatment with 100 ng/ml hBMP2 protein, examined as a
positive control. However, BMPs have a molecular mass of
20–25 kDa and usually act as a homodimer, whereas about
120-kDa hNELL1-VH protein is probably a homotrimer in
solution [5]. Therefore, comparison of their concentrations in
a molar basis (hBMP2, 100 ng/ml = 2.5 nM; hNELL1-VH,
100 ng/ml = 0.28 nM) suggests that hNELL1-VH protein has
an ALP inducing activity at much lower concentrations than
hBMP2 protein. Other osteomarkers, osteopontin (OPN)
and OCN, which are expressed in the diﬀerentiated osteo-
blast following ALP, were also induced in the RFC cells at 6
and 9 days, respectively, after the treatment with 100 ng/ml
hNELL1-VH protein, as eﬀectively as hBMP2 protein
(Fig. 2B and C). Similar results have been obtained with a
mouse osteoblast cell line MC3T3-E1 and a human osteosar-
coma cell line Saos-2 (data not shown). These results clearly
show that hNELL1-VH protein indeed induces the expression
of osteomarkers in RFC cells when added extracellularly even
at a very low concentration.3.2. Activation of MAPK
During the bone diﬀerentiation of osteogenic cells, the
MAPK signaling cascade is activated along with the expression
Fig. 2. Induction of osteomarkers by hNELL1-VH. RFC cells were
treated with various concentrations (or 100 ng/ml in B and C) of the
puriﬁed hNELL1-VH protein or 100 ng/ml hBMP2 protein. (A)
Intracellular ALP activities in the 3-day cultured cells were measured.
(B) Amounts of OPN secreted into the 6-day cultured medium were
measured. (C) Amounts of OCN secreted into the 9-day cultured
medium were measured. Each value represents the means ± S.E.M. of
at least four times measurements. (*) indicate that the data are
signiﬁcantly diﬀerent from the control (P < 0.005, t-test).
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of treatment of serum-starved RFC cells with the puriﬁed
hNELL1-VH protein on the phosphorylation of proteins in-
volved in the MAPK signaling cascade. As shown in Fig. 3A
(left panels), ERK1/2 and JNK1/2/3 were phosphorylated sig-
niﬁcantly after 10 and 20 min, respectively, of the treatment
with hNELL1-VH protein. Based on the densitometric intensi-
ties, the amounts of phosphorylated ERK1/2 and JNK1/2/3
were estimated to have increased by about 22-folds as com-
pared to the untreated RFC cells. Weak phosphorylation of
p38a/b/c (about 5-folds that of untreated cells) was also ob-
served after 10 min. These phosphorylated MAPK members
were detected only within 30 min after the treatment of RFC
cells, indicating that hNELL1-VH protein induces transient
rather than sustained (>12 h) activation of the MAPK mem-
bers. For comparison, the phosphorylated forms of ERK1/2,
JNK1/2/3, and p38a/b/c also increased by about 20, 21, and
17-folds, respectively, in a similar timing after the treatment
of RFC cells with hBMP2 protein (middle panels). With a
mouse mesenchymal stem cell line C3H10T1/2, both
hNELL1-VH and hBMP2 proteins induced the phosphoryla-
tion of ERK1/2 and JNK1/2/3 at comparable levels after
10 min of the treatment (see Figs. 3B and 4A). With a human
osteosarcoma cell line Saos-2, the two proteins similarly in-duced the phosphorylation of ERK1/2 after 10 min but sus-
tained that of ERK2 even after 60 min (Fig. 3C) and several
more hours (data not shown). In mouse myoblast-like
C2C12 cells (see Supplementary Fig. 2), hNELL1-VH protein
was found to activate only JNK1/2/3 very weakly (about 1.3-
fold) within 10 min. As reported previously [9], both proteins
synergistically but weakly activated JNK1/2/3 (about 1.9-fold)
in C2C12 cells. Taken together, these results demonstrate that
hNELL1-VH protein per se can activate the MAPK signaling
cascade within 10 min in various osteoblastic cells, like
hBMP2. The duration of the MAPK phosphorylation, how-
ever, varies from 30 min to at least several hours among the
osteoblastic cells. It is noteworthy that a NELL1 homologue,
NELL2 functions as a survival factor for primary cultured
neurons also through the activation of ERK and JNK [11].
3.3. Eﬀects of RAS siRNA on OPN expression
The OPN expression was induced by the 6 days treatment of
hNELL1-VH protein in C3H10T1/2 (Fig. 4B) and RFC cells
(see Supplementary Fig. 3), while not in the hNELL1-VH-trea-
ted C2C12 cells as reported previously [9], which may be
caused by the weak activation of MAPK (i.e., JNK1/2/3) in
the hNELL1-VH-treated C2C12 cells (see below and Supple-
mentary Fig. 2). We next investigated the eﬀects of Ras small
interfering RNA (siRNA) on the OPN expression in the
hNELL1-VH-treated C3H10T1/2 cells. As shown in Fig. 4A,
Ras siRNA diminished the expression of Ras protein and sup-
pressed signiﬁcantly the hNELL1-VH-induced ERK1/2 activa-
tion and partially the hNELL1-VH-induced JNK1/2/3
activation, while not aﬀected the phosphorylation state of
p38a/b/c. The hNELL1-VH-induced OPN expression was also
suppressed by Ras siRNA (Fig. 4B). In the hNELL1-VH-trea-
ted RFC cells, similar inhibitory eﬀects were observed by using
both a MEK inhibitor PD98059 and a JNK inhibitor
SP600125 (see Supplementary Fig. 3). Various osteogenic stim-
uli, including BMP2, are known to induce the expression of
osteomarkers (ALP, OPN, OCN, and so on) along with the
activation of MAPK signaling molecules [12]. The activation
of ERK and JNK, but not of p38, is necessary for the
hNELL1-VH-induced OPN expression.3.4. Phosphorylation of smad proteins
The phosphorylation of Smad1/5/8, which is usually trig-
gered by the BMP-dependent oligomerization of BMP recep-
tors type I (BMP-R1) and type II (BMP-R2) [13], was
examined in the hNELL1-VH protein-treated RFC and Saos-
2 cells by Western blotting using an anti-phosphorylated
Smad1/5/8 antibody (Fig. 5A and B). Although hBMP2 protein
immediately induced the sustained phosphorylation of Smad1/
5/8 in both cells (right panels), hNELL1-VH protein showed
almost no eﬀect on the phosphorylation state of Smad1/5/8.
Smad4 is then translocated from the cytoplasm to the nucleus
by forming an oligomer with phosphorylated Smad1/5/8
[13]. Immunocytochemical observation of hBMP2-treated
C3H10T1/2 cells revealed rapid nuclear translocation of
Smad4, whereas in the hNELL1-treated cells Smad4 remained
in the cytoplasm even after 60 min of the treatment (Fig. 5C),
conﬁrming the absence of phosphorylation of Smad1/5/8 after
the treatment with hNELL1-VH protein.
Next, the promoter region (from 985 to 0 bp) of the human
Id1 gene, one of the Smad-dependent BMP target genes, was
Fig. 3. Activation of MAPK by hNELL1-VH. RFC cells (A), C3H10T1/2 cells (B), and Saos-2 cells (C) were treated with 100 ng/ml hNELL1-VH
protein (derived from 125 ll medium), 100 ng/ml hBMP2 protein, or mock sample (derived from 2 ml medium) for the indicated times. Cell lysates
(15 lg protein) were analyzed by Western blotting either with anti-phospho-ERK1/2 (p-ERK1/2), anti-phospho-JNK1/2/3 (p-JNK1/2/3), and anti-
phospho-p38a/b/c (p-p38) antibodies. Anti-ERK1/2 (ERK1/2), anti-JNK1/2/3 (JNK1/2/3), anti-p38a/b/c (p38), and anti-b-actin (actin) antibodies
were used as internal controls. All experiments were repeated more than three times, and representative data are shown.
Fig. 4. Eﬀects of Ras siRNA on OPN expression. C3H10T1/2 cells were transfected with Ras siRNA on 1st day, and then treated with 100 ng/ml
hNELL1-VH protein for 15 min on 2nd day. (A) Cell lysates (15 g protein) were analyzed by Western blotting as described in Fig. 3. (B) Cells were
cultured for 6 days in the presence of hNELL1-VH. Amounts of OPN secreted into the culture medium were measured by ELISA on 7th day. Each
value represents the means ± S.E.M. of triplicate measurements. (*) indicate that the data are signiﬁcantly diﬀerent from the control (DMSO,
P < 0.005, t-test).
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Fig. 5. Phosphorylation of Smad proteins. RFC (A) and Saos-2 (B) cells were treated with 100 ng/ml hNELL1-VH or 100 ng/ml hBMP2 protein for
the indicated times. Cell lysates (15 lg protein) were analyzed by Western blotting with anti-phospho-Smad1/5/8 (p-Smad1/5/8), anti-Smad1/5/8
(Smad1/5/8), and anti-actin (actin) antibodies. All experiments were repeated at least three times, and representative data are shown. (C) C3H10T1/2
cells were treated with 100 ng/ml hNELL1-VH or 100 ng/ml hBMP2 protein at 37 C for 1 h. Intracellular localization of Smad4 was analyzed by the
immunocytochemical method using anti-Smad4 and Alexa-546-conjugated anti-mouse IgG antibodies (bar, 50 lm). (D) RFC cells transformed with
the luciferase gene under the Id1-985 or mutated Id1 (Id1-985MutB) promoter were treated with 10 or 100 ng/ml hNELL1-VH or 100 ng/ml hBMP2
protein for 24 h. Smad-dependent transcriptional activity was determined as intracellular luciferase activity. Each value represents the
means ± S.E.M. of four times measurements. (*) indicates that the data are signiﬁcantly diﬀerent from the control (P < 0.005, t-test).
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(Id985-luc) [14]. RFC cells harboring the Id985-luc gene were
treated with either hNELL1-VH or hBMP2 protein for 2 days,
and the luciferase activity in each cell lysate was measured
(Fig. 5D). While the hBMP2 treatment approximately doubled
the activity of the control cells, the hNELL1-VH treatment
showed essentially no eﬀect on the activity. When the RFC
cells harboring the Id985muBt-luc gene, an Id985-luc gene lack-
ing the Smad4-binding sites [14], were treated with hNELL1-VH or hBMP2 protein, the luciferase activity was not aﬀected.
These data unequivocally show that the NELL1-induced sig-
naling pathway does not involve the phosphorylation of Smad
proteins at least in osteoblastic cells.
3.5. Phosphorylation of Runx2
The transcription factor Runx2 is a key master regulator of
osteoblast diﬀerentiation, enhancing transcription of the genes
for osteomarker proteins [15]. Indeed, Runx2-knockout mice
Fig. 6. Phosphorylation of Runx2. C3H10T1/2 cells were transfected
with Ras siRNA on 1st day, and then treated with 100 ng/ml hNELL1-
VH protein for 15 min on 2nd day. The anti-Runx2 immunoprecip-
itates were analyzed by Western blotting using an anti-phosphoserine
antibody (anti-pSer) (upper panel) or an anti-Runx2 antibody (anti-
Runx2) (lower panel). All experiments were repeated more than three
times, and representative data are shown.
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[16]. Upon stimulation of the osteoblastic cells with FGF2,
IGF1, or various ECM proteins, the transcription factor
Runx2 is phosphorylated (namely activated) by ERK1/2 and
then plays an important role in the osteoblast diﬀerentiation
[17–20]. In the present study, the eﬀect of Ras siRNA on the
phosphorylation of Runx2 was investigated in the hNELL1-
VH-treated C3H10T1/2 cells. As revealed by Western blotting
of the anti-Runx2 immunoprecipitates with an anti-phospho-
Ser antibody (Fig. 6), Runx2 was signiﬁcantly phosphorylated
in the NELL1-treated cells. Based on the above results
(Fig. 4A) and suppression of Runx2 phosphorylation with
Ras siRNA, Runx2 is phosphorylated presumably by ERK1/
2. In the hNELL1-VH-treated RFC cells, similar inhibitory
eﬀects were observed by using a MEK inhibitor PD98059
(see Supplementary Fig. 4). In summary, Runx2 is most likely
a transcription factor located downstream of the NELL1 sig-
naling cascade. The Smad-independent Ras-MAPK signaling
cascade appears to be a major route in the NELL1-induced
expression of osteomarkers, namely in the osteoblastic diﬀer-
entiation.Fig. 7. Detection of Tyr-phosphorylated proteins interacting with hNELL1-V
2, and 5 min. Cell lysates were subjected to immunoprecipitation with either m
blotting using an anti-phosphotyrosine antibody 4G10. Protein G released fro
Tyr-phosphorylated proteins are indicated by arrowheads.3.6. Immediate accumulation of Tyr-phosphorylated proteins
The puriﬁed NELL1 homolog, NELL2, did not interact
with a soluble form of BMP-R1 in an in vitro surface plasmon
resonance assay [21] (unpublished data). In addition, although
NELL2 also contains 6 EGF-like domains (see Fig. 1), NELL2
did not interact with the ErbB superfamily (ErbB-1–4) in an
immunoprecipitation assay (unpublished data). The results de-
scribed so far have suggested that the NELL1 protein interacts
with an unidentiﬁed speciﬁc receptor that is associated with the
Ras-MAPK cascade. As a preliminary approach toward iden-
tiﬁcation of the NELL1 receptor and other closely juxtaposed
proteins, hNELL1-VH-interacting proteins were immunopre-
cipitated immediately after the treatment of RFC cells with
hNELL1-VH protein and the immunoprecipitates were ana-
lyzed by Western blotting with an anti-phospho-Tyr antibody.
As shown in Fig. 7B, about 45- and 55-kDa proteins were
identiﬁed as those directly or indirectly interacting with
hNELL1-VH protein and being Tyr-phosphorylated in a very
early stage of NELL1-binding to the cells. A slightly Tyr-phos-
phorylated protein of about 200 kDa was also found after
5 min. Amounts of these proteins reached a plateau at 5 min
after the hNELL1-VH treatment and remained unchanged
even after 20 min. Similar results were obtained with
C3H10T1/2 cells treated with hNELL1-VH protein (data not
shown). Collectively, it is suggested that NELL1 forms an
extracellular complex with its speciﬁc receptor and then the
complex facilitates either activation of Tyr-kinases, inactiva-
tion of Tyr phosphatases, or intracellular recruitment of
Tyr-phosphorylated proteins.
3.7. Putative NELL1 receptor
Recently, various ECM proteins (e.g., laminin 5, ﬁbronectin,
vitronectin, and TSP1/2) have been revealed to interact with
the integrin family [22]. The ligand-bound integrin transduces
the signals through activation of the focal adhesion kinase
(FAK), followed by indirect activation of the Ras-MAPK cas-H. RFC cells were treated with 100 ng/ml hNELL1-VH protein for 0,
ouse IgG (A) or an anti-V5 tag antibody (B) and analyzed by Western
m the aﬃnity resin was detected as non-speciﬁc bands (white asterisks).
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Runx2 [23]. The signals elicited by mechanical force also utilize
a similar signaling cascade from integrin to Runx2 [24]. In the
amino acid sequence comparison between hNELL1 and vari-
ous ECM proteins (Fig. 1), the N-terminal domain of hNELL1
(aa 85–174) shows a high degree of similarity with the laminin
G domain of ECM proteins [25]. In particular, human TSP1
shows the highest identity (22%) with the corresponding region
of hNELL1. The laminin G domain serves in the interaction
with integrins and a 67-kDa laminin receptor [26]. Mutational
analyses of TSP1 and TSP2 have demonstrated that a Glu res-
idue (Glu-90) between b-strands D and E is important for the
interaction with integrin a6b1, which is conserved in the simi-
lar positions of hNELL1 [22] (Fig. 1). Taken together, the re-
sults reported in this paper show that NELL1 is a novel
osteogenic factor that transduces the osteogenic signals
through the pathway involving Ras-MAPK and Runx2, but
not involving BMP receptors and Smads. It is highly likely that
an integrin-related molecule and Tyr-kinases are involved in
the NELL1-signaling cascade, triggered by binding to the
NELL1-speciﬁc receptor(s), whose identiﬁcation is under way.
Acknowledgements: We thank Prof. Ryutaro Kamijo (Showa Univer-
sity Dental School) for helpful discussion and Prof. Takenobu Katagiri
(Saitama Medical University) for supplying the Id1 vectors. This study
was supported in part by a Grant-in-Aid from JSPS (to SK; No.
15300126).Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.
2007.12.006.
References
[1] Hughes, F.J., Turner, W., Belibasakis, G. and Martuscelli, G.
(2000) Eﬀects of growth factors and cytokines on osteoblast
diﬀerentiation. Periodontology 41, 48–72.
[2] Canalis, E., Economides, A.N. and Gazzerro, E. (2003) Bone
morphogenetic proteins, their antagonists, and the skeleton.
Endocrinology 24, 218–235.
[3] Chen, D., Zhao, M. and Mundy, G.R. (2004) Bone morphoge-
netic proteins. Growth Factors 22, 233–241.
[4] Ting, K., Vastardis, H., Mulliken, J.B., Soo, C., Tieu, A., Do, H.,
Kwong, E., Bertolami, C.N., Kawamoto, H., Kuroda, S. and
Longaker, M.T. (1999) Human NELL-1 expressed in unilateral
coronal synostosis. J. Bone Miner. Res. 14, 80–89.
[5] Kuroda, S., Oyasu, M., Kawakami, M., Kanayama, N., Taniz-
awa, K., Saito, N., Abe, T., Matsuhashi, S. and Ting, K. (1999)
Biochemical characterization and expression analysis of neural
thrombospondin-1-like proteins NELL1 and NELL2. Biochem.
Biophys. Res. Commun. 265, 79–86.
[6] Zhang, X., Kuroda, S., Carpenter, D., Nishimura, I., Soo, C.,
Moats, R., Iida, K., Wisner, E., Hu, F.Y., Miao, S., Beanes, S.,
Dang, C., Vastardis, H., Longaker, M., Tanizawa, K., Kanay-
ama, N., Saito, N. and Ting, K. (2002) Craniosynostosis in
transgenic mice overexpressing Nell-1. J. Clin. Invest. 18, 2126–
2134.
[7] Desai, J., Shannon, M.E., Johnson, M.D., Ruﬀ, D.W., Hughes,
L.A., Kerley, M.K., Carpenter, D.A., Johnson, D.K., Rinchik,
E.M. and Culiat, C.T. (2006) Nell1-deﬁcient mice have reduced
expression of extracellular matrix proteins causing cranial and
vertebral defects. Hum. Mol. Genet. 15, 1329–1341.
[8] Aghaloo, T., Cowan, C.M., Chou, Y.F., Zhang, X., Lee, H.,
Miao, S., Hong, N., Kuroda, S., Wu, B., Ting, K. and Soo, C.
(2006) Nell-1-induced bone regeneration in calvarial defects. Am.
J. Pathol. 169, 903–915.[9] Cowan, C.M., Jiang, X., Hsu, T., Soo, C., Zhang, B., Wang, J.Z.,
Kuroda, S., Wu, B., Zhang, Z., Zhang, X. and Ting, K. (2007)
Synergistic eﬀects of Nell-1 and BMP-2 on the osteogenic
diﬀerentiation of myoblasts. J. Bone Miner. Res. 22, 918–930.
[10] Xiao, G., Gopalakrishnan, R., Jiang, D., Reith, E., Benson, M.D.
and Franceschi, R.T. (2002) Bone morphogenetic proteins,
extracellular matrix, and mitogen-activated protein kinase signal-
ing pathways are required for osteoblast-speciﬁc gene expression
and diﬀerentiation in MC3T3-E1 cells. J. Bone Miner. Res. 17,
101–110.
[11] Aihara, K., Kuroda, S., Kanayama, N., Matsuyama, S., Taniz-
awa, K. and Horie, M. (2004) A neuron-speciﬁc EGF family
protein, NELL2, promotes survival of neurons through mitogen-
activated protein kinases. Brain Res. Mol. Brain Res. 116,
86–93.
[12] Schindeler, A. and Little, D.G. (2006) Ras-MAPK signaling in
osteogenic diﬀerentiation: friend or foe? J. Bone Miner. Res. 21,
1331–1338.
[13] Miyazono, K., Maeda, S. and Imamura, T. (2005) BMP receptor
signaling: transcriptional targets, regulation of signals, and
signaling cross-talk. Cytokine Growth Factor Rev. 16, 251–263.
[14] Katagiri, T., Imada, M., Yanai, T., Suda, T., Takahashim, N. and
Kamijo, R. (2002) Identiﬁcation of a BMP-responsive element
in Id1, the gene for inhibition of myogenesis. Genes Cell. 7, 949–
960.
[15] Ducy, P., Zhang, R., Geoﬀroy, V., Ridall, A.L. and Karsenty, G.
(1997) Osf2/Cbfa1: a transcriptional activator of osteoblast
diﬀerentiation. Cell 89, 747–754.
[16] Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour,
K.C., Rosewell, I.R., Stamp, G.W., Beddington, R.S., Mundlos,
S., Olsen, B.R., Selby, P.B. and Owen, M.J. (1997) Cbfa1, a
candidate gene for cleidocranial dysplasia syndrome, is essential
for osteoblast diﬀerentiation and bone development. Cell 30, 765–
771.
[17] Xiao, G., Jiang, D., Gopalakrishnan, R. and Franceschi, R.T.
(2002) Fibroblast growth factor 2 induction of the osteocalcin
gene requires MAPK activity and phosphorylation of the osteo-
blast transcription factor, Cbfa1/Runx2. J. Biol. Chem. 277,
36181–36187.
[18] Qiao, M., Shapiro, P., Kumar, R. and Passaniti, A. (2004)
Insulin-like growth factor-1 regulates endogenous RUNX2 activ-
ity in endothelial cells through a phosphatidylinositol 3-kinase/
ERK-dependent and Akt-independent signaling pathway. J. Biol.
Chem. 279, 42709–42718.
[19] Xiao, G., Jiang, D., Thomas, P., Benson, M.D., Guan, K.,
Karsenty, G. and Franceschi, R.T. (2000) MAPK pathways
activate and phosphorylate the osteoblast-speciﬁc transcription
factor, Cbfa1. J. Biol. Chem. 275, 4453–4459.
[20] Klees, R.F., Salasznyk, R.M., Kingsley, K., Williams, W.A.,
Boskey, A. and Plopper, G.E. (2005) Laminin-5 induces osteo-
genic gene expression in human mesenchymal stem cells through
an ERK-dependent pathway. Mol. Biol. Cell 16, 881–890.
[21] Natsume, T., Tomita, S., Iemura, S., Kinto, N., Yamaguchi, A.
and Ueno, N. (1997) Interaction between soluble type I receptor
for bone morphogenetic protein and bone morphogenetic protein-
4. J. Biol. Chem. 272, 11535–11540.
[22] Calzada, M.J., Sipes, J.M., Krutzsch, H.C., Yurchenco, P.D.,
Annis, D.S., Mosher, D.F. and Roberts, D.D. (2004) Recognition
of the N-terminal modules of thrombospondin-1 and thrombo-
spondin-2 by alpha6beta1 integrin. J. Biol. Chem. 278, 40679–
40687.
[23] Salasznyk, R.M., Klees, R.F., Boskey, A. and Plopper, G.E.
(2007) Activation of FAK is necessary for the osteogenic
diﬀerentiation of human mesenchymal stem cells on laminin-5.
J. Cell Biochem. 100, 499–514.
[24] Kanno, T., Takahashi, T., Tsujisawa, T., Ariyoshi, W. and
Nishihara, T. (2007) Mechanical stress-mediated Runx2 activa-
tion is dependent on Ras/ERK1/2 MAPK signaling in osteoblasts.
J. Cell Biochem. 101, 1266–1277.
[25] Hohenester, E., Tisi, D., Talts, J.F. and Timpl, R. (1999) The
crystal structure of a laminin G-like module reveals the molecular
basis of alpha-dystroglycan binding to laminins, perlecan, and
agrin. Mol. Cell 4, 783–792.
[26] Givant-Horwitz, V., Davidson, B. and Reich, R. (2005) Laminin-
induced signaling in tumor cells. Cancer Lett. 223, 1–10.
